Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdatifan and Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Phase 3Recruiting
- Sponsor
- Arcus Biosciences
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of casdatifan in clear cell renal cell carcinoma (ccRCC), sponsored by Arcus Biosciences. Started Sep 2025; status: recruiting.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07011719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011719.